Sri Lanka to fix prices for 90-pct of imported medicines within a year: NMRA

ECONOMYNEXT — Sri Lanka’s National Medicines Regulatory Authority (NMRA) expects to enforce maximum retail prices (MRPs) for roughly 90 percent of imported medicines over the coming year, NMRA chairman Ananda Wijewickrama said.

The regulator is carrying out brand-specific price determinations across more than 6,000 registered formulations as pharmaceutical companies submit applications for their annual import permits.

“These 6,000 medicines exist under various brand names. For example, if we take the medicine called Metformin, I think it is registered under more than 30 brand names. We determine prices for all 30 of these separately,” Wijewickrama said.

The price-setting mechanism would encompass the majority of active imports within a 12-month period, he said.

While certain registered medicines imported only for sporadic state tenders may fall outside this cycle, active commercial imports will be capped.

Pricing determinations will remain an ongoing process to adjust for raw material costs and exchange rate shifts.

To prevent inflated transfer pricing, import costs (Cost, Insurance, and Freight – CIF) are benchmarked directly against domestic retail rates in the manufacturing nations, such as India or Bangladesh.

All approved maximum retail prices will be published on the NMRA website for consumer reference, NMRA officials told reporters.

Standardizing MRPs will eliminate regional disparities where retail pharmacies in areas like Jaffna, Anuradhapura, and Colombo sell identical products at differing prices, Wijewickrama claimed.

While setting MRPs or price caps on medicines is intended to protect patients from price gouging, and lower healthcare costs, critics point out that international pharmaceutical companies would opt to withdraw products from a country, especially a small market like Sri Lanka, rather than sell at a loss.

This would take away a patient’s access to possibly higher-quality meds and leave them with generic meds. (Colombo/Oct01/2026)